Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q1 2015 · 10-Q
Revenue$12.49M$12.49M+597.2% vs Q1 2014 Net Income-$34.88M-$34.88MN/M vs Q1 2014 EPS Diluted-$0.34-$0.34N/M vs Q1 2014 Operating Income-$33,871,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
Free Cash Flowderived-$43,794,000N/M Margins · derivedOperating margin-271.1%+1209.2 pt vs Q1 2014
Net margin-279.2%+1287.5 pt vs Q1 2014
ended Mar 31, 2016 · filed May 5, 2016 · 35 d after period end